Nowadays, numerous phase III clinical trials have shown that various PARP inhibitors can improve treatment outcomes in both early and advanced germline BRCA1/2 (gBRCA1/2)-mutant breast cancer, as well as achieve a better quality of life [4–7], opposed to cytotoxic chemotherapy. Here, BRCA1 is linked to breast carcinoma.